Laboratory and Clinical Studies of Gentamicin

Publisher Website
Google Scholar
Abstract
Laboratory and clinical studies of a new broad spectrum antibiotic, gentamicin, are reported. Its activity against Escherichia coli, Pseudomonas, Aerobacter-Klebsiella and both indole positive and negative Proteus strains was superior to the other commonly used antibiotics. It was bactericidal, and in vitro resistance developed slowly. Gentamicin administered intramuscularly in doses of 30 mg (2-3 times daily) caused slight to moderate pain at the injection site. Serum gentamicin levels seldom exceeded 4.0 [mu]g/ml, but urine concentrations were high. There was a transient elevation of the blood urea-N, and proteinuria in a few patients. One uremic patient had vestibular damage due to a high serum concentration of gentamicin. Gentamicin may be a valuable agent for the treatment of urinary infections caused by certain resistant gram-negative bacteria.

This publication has 0 references indexed in Scilit: